India, Nov. 18 -- Allarity Therapeutics Inc. (ALLR), a clinical-stage pharmaceutical company, on Wednesday announced receiving a patent from the U.S. Patent and Trademark Office (USPTO) covering treatment regimens that use lead drug candidate Stenoparib for ovarian cancer and other solid tumors.
The document was assigned U.S. Patent No. 12,806,205, arising from U.S. Patent Application No. 18/606,590.
Stenoparib is an orally available, small molecule dual WNT and PARP inhibitor designed to block aberrant pathway signaling that leads to the progression of numerous drug-resistant cancers.
The latest patent received covers 36 claims relating to the twice-daily, oral administration of stenoparib with specified dose levels and treatment schedu...